Roivant Capital Expenditures vs Stock Based Compensation Analysis

ROIV Stock

USD 12.17 0.35 2.96%

Roivant Sciences financial indicator trend analysis is much more than just breaking down Roivant Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Roivant Sciences is a good investment. Please check the relationship between Roivant Sciences Capital Expenditures and its Stock Based Compensation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roivant Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Roivant Stock please use our How to Invest in Roivant Sciences guide.

Capital Expenditures vs Stock Based Compensation

Capital Expenditures vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Roivant Sciences Capital Expenditures account and Stock Based Compensation. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Roivant Sciences' Capital Expenditures and Stock Based Compensation is 0.16. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Roivant Sciences, assuming nothing else is changed. The correlation between historical values of Roivant Sciences' Capital Expenditures and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Roivant Sciences are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Capital Expenditures i.e., Roivant Sciences' Capital Expenditures and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

0.16

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Roivant Sciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Roivant Sciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Roivant Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Roivant Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roivant Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Roivant Stock please use our How to Invest in Roivant Sciences guide.At this time, Roivant Sciences' Tax Provision is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 12.74 in 2024, whereas Selling General Administrative is likely to drop slightly above 530.9 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	7.0M	28.0M	34.8M	36.5M
Depreciation And Amortization	5.9M	18.9M	22.0M	20.9M

Interest Expense Depreciation And Amortization

Roivant Sciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Property Plant Equipment
Total Assets		0.74	-0.12	0.3	1.0	-0.74	0.49	0.59	0.4	-0.99	0.86	0.78	1.0	0.66	0.49	0.32	1.0	0.96	0.72	0.74	-0.64	0.79	0.69	1.0	0.03	0.53
Short Long Term Debt Total	0.74		-0.11	0.53	0.69	-0.83	0.4	0.78	0.77	-0.72	0.34	0.96	0.72	0.95	0.83	0.34	0.73	0.77	0.91	1.0	-0.73	0.98	0.96	0.71	0.48	0.51
Other Current Liab	-0.12	-0.11		0.78	-0.16	0.3	-0.75	-0.55	-0.33	0.17	-0.16	-0.16	-0.16	-0.19	0.36	-0.53	-0.16	0.02	-0.09	-0.12	0.62	-0.13	0.16	-0.12	0.39	-0.57
Total Current Liabilities	0.3	0.53	0.78		0.24	-0.24	-0.43	0.01	0.24	-0.24	-0.01	0.45	0.26	0.44	0.83	-0.3	0.26	0.45	0.47	0.52	0.1	0.5	0.73	0.28	0.7	-0.23
Total Stockholder Equity	1.0	0.69	-0.16	0.24		-0.71	0.51	0.57	0.34	-1.0	0.9	0.74	1.0	0.61	0.42	0.33	1.0	0.95	0.67	0.7	-0.63	0.74	0.63	1.0	-0.04	0.54
Other Liab	-0.74	-0.83	0.3	-0.24	-0.71		-0.74	-0.92	-0.84	0.73	-0.39	-0.9	-0.74	-0.92	-0.67	-0.52	-0.74	-0.63	-0.96	-0.82	0.89	-0.9	-0.73	-0.71	-0.07	-0.69
Net Tangible Assets	0.49	0.4	-0.75	-0.43	0.51	-0.74		0.85	0.58	-0.51	0.41	0.48	0.51	0.55	0.1	0.82	0.51	0.3	0.56	0.4	-0.91	0.45	0.18	0.47	-0.39	0.9
Property Plant And Equipment Net	0.59	0.78	-0.55	0.01	0.57	-0.92	0.85		0.89	-0.58	0.26	0.8	0.59	0.9	0.55	0.69	0.6	0.5	0.85	0.78	-0.97	0.8	0.63	0.55	0.1	0.81
Current Deferred Revenue	0.4	0.77	-0.33	0.24	0.34	-0.84	0.58	0.89		-0.35	-0.08	0.75	0.39	0.91	0.69	0.39	0.39	0.37	0.81	0.77	-0.77	0.79	0.69	0.35	0.41	0.51
Net Debt	-0.99	-0.72	0.17	-0.24	-1.0	0.73	-0.51	-0.58	-0.35		-0.89	-0.77	-1.0	-0.63	-0.43	-0.34	-1.0	-0.94	-0.7	-0.72	0.65	-0.77	-0.65	-1.0	0.04	-0.55
Retained Earnings	0.86	0.34	-0.16	-0.01	0.9	-0.39	0.41	0.26	-0.08	-0.89		0.41	0.87	0.22	0.04	0.3	0.87	0.79	0.33	0.34	-0.4	0.39	0.27	0.88	-0.34	0.45
Accounts Payable	0.78	0.96	-0.16	0.45	0.74	-0.9	0.48	0.8	0.75	-0.77	0.41		0.77	0.93	0.76	0.31	0.77	0.74	0.95	0.95	-0.76	0.99	0.9	0.75	0.28	0.5
Cash	1.0	0.72	-0.16	0.26	1.0	-0.74	0.51	0.59	0.39	-1.0	0.87	0.77		0.64	0.45	0.33	1.0	0.95	0.7	0.73	-0.65	0.77	0.66	1.0	0.0	0.55
Non Current Assets Total	0.66	0.95	-0.19	0.44	0.61	-0.92	0.55	0.9	0.91	-0.63	0.22	0.93	0.64		0.84	0.45	0.65	0.65	0.96	0.95	-0.82	0.95	0.89	0.62	0.42	0.6
Non Currrent Assets Other	0.49	0.83	0.36	0.83	0.42	-0.67	0.1	0.55	0.69	-0.43	0.04	0.76	0.45	0.84		0.18	0.46	0.57	0.83	0.83	-0.44	0.8	0.92	0.45	0.67	0.28
Other Assets	0.32	0.34	-0.53	-0.3	0.33	-0.52	0.82	0.69	0.39	-0.34	0.3	0.31	0.33	0.45	0.18		0.34	0.21	0.44	0.34	-0.8	0.29	0.17	0.29	-0.22	0.96
Cash And Short Term Investments	1.0	0.73	-0.16	0.26	1.0	-0.74	0.51	0.6	0.39	-1.0	0.87	0.77	1.0	0.65	0.46	0.34		0.95	0.71	0.73	-0.65	0.77	0.66	1.0	0.0	0.55
Net Receivables	0.96	0.77	0.02	0.45	0.95	-0.63	0.3	0.5	0.37	-0.94	0.79	0.74	0.95	0.65	0.57	0.21	0.95		0.66	0.78	-0.52	0.78	0.77	0.96	0.27	0.42
Common Stock Shares Outstanding	0.72	0.91	-0.09	0.47	0.67	-0.96	0.56	0.85	0.81	-0.7	0.33	0.95	0.7	0.96	0.83	0.44	0.71	0.66		0.9	-0.8	0.95	0.86	0.68	0.24	0.6
Non Current Liabilities Total	0.74	1.0	-0.12	0.52	0.7	-0.82	0.4	0.78	0.77	-0.72	0.34	0.95	0.73	0.95	0.83	0.34	0.73	0.78	0.9		-0.73	0.97	0.96	0.71	0.51	0.51
Other Current Assets	-0.64	-0.73	0.62	0.1	-0.63	0.89	-0.91	-0.97	-0.77	0.65	-0.4	-0.76	-0.65	-0.82	-0.44	-0.8	-0.65	-0.52	-0.8	-0.73		-0.75	-0.55	-0.61	0.05	-0.91
Other Stockholder Equity	0.79	0.98	-0.13	0.5	0.74	-0.9	0.45	0.8	0.79	-0.77	0.39	0.99	0.77	0.95	0.8	0.29	0.77	0.78	0.95	0.97	-0.75		0.93	0.76	0.37	0.49
Total Liab	0.69	0.96	0.16	0.73	0.63	-0.73	0.18	0.63	0.69	-0.65	0.27	0.9	0.66	0.89	0.92	0.17	0.66	0.77	0.86	0.96	-0.55	0.93		0.66	0.63	0.33
Total Current Assets	1.0	0.71	-0.12	0.28	1.0	-0.71	0.47	0.55	0.35	-1.0	0.88	0.75	1.0	0.62	0.45	0.29	1.0	0.96	0.68	0.71	-0.61	0.76	0.66		0.01	0.51
Short Term Debt	0.03	0.48	0.39	0.7	-0.04	-0.07	-0.39	0.1	0.41	0.04	-0.34	0.28	0.0	0.42	0.67	-0.22	0.0	0.27	0.24	0.51	0.05	0.37	0.63	0.01		-0.19
Property Plant Equipment	0.53	0.51	-0.57	-0.23	0.54	-0.69	0.9	0.81	0.51	-0.55	0.45	0.5	0.55	0.6	0.28	0.96	0.55	0.42	0.6	0.51	-0.91	0.49	0.33	0.51	-0.19

Click cells to compare fundamentals

Roivant Sciences Account Relationship Matchups

Roivant Sciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.5B	2.7B	2.6B	2.4B	7.2B	7.6B
Short Long Term Debt Total	180.9M	245.0M	283.9M	481.4M	499.7M	336.2M
Other Current Liab	70.4M	180.2M	127.5M	169.2M	177.0M	166.2M
Total Current Liabilities	92.1M	219.0M	184.4M	272.4M	266.8M	228.4M
Total Stockholder Equity	2.0B	1.8B	1.7B	1.2B	6.0B	6.3B
Other Liab	103.2M	76.1M	66.8M	80.6M	72.5M	71.0M
Net Tangible Assets	2.0B	1.8B	1.7B	1.0B	1.2B	1.6B
Property Plant And Equipment Net	73.9M	77.0M	86.9M	92.3M	66.0M	74.7M
Current Deferred Revenue	3.6M	5.9M	10.1M	12.4M	4.2M	6.9M
Net Debt	(2.0B)	(1.8B)	(1.8B)	(1.2B)	(6.0B)	(5.7B)
Retained Earnings	(1.1B)	(1.9B)	(2.8B)	(3.8B)	576.2M	605.0M
Accounts Payable	10.3M	20.6M	34.6M	37.8M	53.2M	29.8M
Cash	2.2B	2.1B	2.1B	1.7B	6.5B	6.9B
Non Current Assets Total	257.8M	402.7M	438.6M	591.0M	490.7M	436.9M
Non Currrent Assets Other	6.7M	36.1M	25.8M	49.5M	39.1M	32.7M
Other Assets	90.4M	100M	25.8M	49.5M	44.5M	46.2M
Cash And Short Term Investments	2.2B	2.1B	2.1B	1.7B	6.5B	6.9B
Net Receivables	15.3M	13.8M	6.7M	37.6M	82.8M	87.0M
Liabilities And Stockholders Equity	2.5B	2.6B	2.6B	2.4B	7.2B	7.6B
Non Current Liabilities Total	276.2M	308.7M	339.3M	509.6M	507.2M	399.7M
Other Current Assets	18.5M	40.4M	79.4M	81.3M	72.7M	82.3M
Other Stockholder Equity	3.1B	3.7B	4.4B	4.9B	5.4B	4.5B
Total Liab	368.4M	527.7M	523.7M	782.0M	774.0M	628.1M
Total Current Assets	2.2B	2.2B	2.1B	1.8B	6.7B	7.1B
Accumulated Other Comprehensive Income	(2.3M)	1.4M	(946K)	(2.6M)	(4.1M)	(3.9M)
Short Term Debt	7.8M	12.3M	11.4M	52.4M	21.9M	23.3M
Property Plant Equipment	73.9M	77.0M	25.9M	39.1M	44.9M	50.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Roivant Stock Analysis

When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC